API Holdings’ stronger Q1 FY27 performance gives its consumer-facing pharmacy business a firmer financial foundation for growth.
API Holdings, the parent company of PharmEasy and Thyrocare, is entering a stronger phase of financial recovery, with its consumer-facing pharmacy business supported by improving group profitability, revenue growth and a debt-free balance sheet.
For the quarter ended June 2026, API Holdings narrowed its Q1 FY27 loss to ₹29.6 crore from ₹145.4 crore a year earlier, while revenue increased 10% year-on-year to ₹1,754 crore. EBITDA turned positive at ₹39.3 crore, compared with an EBITDA loss of ₹12.8 crore in the year-ago quarter.
The company’s improved financial position follows the repayment of ₹1,050 crore in outstanding debt, making API Holdings debt-free. The move marks an important step in strengthening the balance sheet after years of financial pressure following its acquisition of diagnostics chain Thyrocare.
PharmEasy remains the group’s consumer-facing digital pharmacy business, operating alongside B2B medicine distributor Ascent, Thyrocare and hospital-focused supply-chain platform Aknamed. The consumer business reported 10% revenue growth in Q1 FY27 to ₹348 crore, while its EBITDA loss narrowed to ₹17 crore from ₹21 crore in the same quarter last year.
The performance comes as online pharmacy platforms continue to compete for consumer demand through digital convenience and healthcare access. PharmEasy competes with Tata 1mg, Reliance-owned Netmeds and Apollo 247, making operational efficiency and sustainable unit economics increasingly important for its consumer business.
API Holdings’ B2B business also showed improvement. Ascent recorded 8% year-on-year revenue growth to ₹1,005.6 crore and posted EBITDA of ₹0.7 crore, compared with an EBITDA loss of ₹17.2 crore a year earlier. Both Ascent and Aknamed reported positive EBITDA during the quarter.
Thyrocare, meanwhile, remained the group’s only profitable arm and reported a 34% jump in net profit to ₹51.3 crore. Its performance has also played a role in API Holdings’ debt reduction strategy. As part of the debt repayment transaction, promoter and holding company Docon Technologies sold a 9.9% stake in Thyrocare through market trades while retaining 51.02%.
API Holdings’ balance-sheet cleanup follows the financial strain created by the ₹4,546 crore Thyrocare acquisition in 2021. The company had subsequently taken on high-cost debt, including a ₹2,280 crore Goldman Sachs loan carrying an annual interest rate of 17–18%.
With debt now repaid, API Holdings has created greater financial headroom for its businesses. For PharmEasy, the development could provide a stronger foundation to focus on consumer growth, digital pharmacy operations and improving economics in India’s competitive online healthcare market building a stronger consumer growth engine.
Source: Based on reporting by ET Retail, with additional editorial adaptation and analysis.
